| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bevacizumab added to chemotherapy increases PFS in ovarian, related cancers
|
OSTERWEIL, NEIL
|
|
2010
|
7 |
8 |
p. 380-381
2 p.
|
artikel
|
| 2 |
Binary dependent variables: logistic regression
|
Norman, Geoffrey R.
|
|
2010
|
7 |
8 |
p. 367-368
2 p.
|
artikel
|
| 3 |
Bosutinib induces high response rates in imatinib-resistant/intolerant CML patients
|
OSTERWEIL, NEIL
|
|
2010
|
7 |
8 |
p. 374-
1 p.
|
artikel
|
| 4 |
Carboplatin-paclitaxel combo extends survival in NSCLC
|
DALES, MARY JO
|
|
2010
|
7 |
8 |
p. 377-378
2 p.
|
artikel
|
| 5 |
Chemoradiotherapy increases local control of invasive bladder cancer
|
OSTERWEIL, NEIL
|
|
2010
|
7 |
8 |
p. 372-373
2 p.
|
artikel
|
| 6 |
Choosing prostate cancer therapy with multimedia software
|
Young, Patrick
|
|
2010
|
7 |
8 |
p. 359-360
2 p.
|
artikel
|
| 7 |
Concurrent chemoradiotherapy for the synchronous presentation of limited-stage small cell and early-stage non-small cell lung cancers
|
Watkins, John M.
|
|
2010
|
7 |
8 |
p. 362-365
4 p.
|
artikel
|
| 8 |
Early palliative care boosts lung cancer survival
|
MACNEIL, JANE SALODOF
|
|
2010
|
7 |
8 |
p. 378-379
2 p.
|
artikel
|
| 9 |
Gemcitabine or capecitabine: does it matter which comes first in treating pancreatic cancer?
|
WENDLING, PATRICE
|
|
2010
|
7 |
8 |
p. 382-383
2 p.
|
artikel
|
| 10 |
Highlights of ASCO: Selected reports from the 46th annual meeting of the American Society of Clinical Oncology
|
WENDLING, PATRICE
|
|
2010
|
7 |
8 |
p. 369-370
2 p.
|
artikel
|
| 11 |
Hormone and HER2 receptor status can change when breast tumors progress
|
WENDLING, PATRICE
|
|
2010
|
7 |
8 |
p. 371-372
2 p.
|
artikel
|
| 12 |
Incidence and risk factors for chemotherapy-induced nausea or vomiting following highly or moderately emetogenic chemotherapy in community oncology practice
|
Feinberg, Bruce A.
|
|
2010
|
7 |
8 |
p. 347-354
8 p.
|
artikel
|
| 13 |
In the pipeline: IL-21 active in metastatic melanoma
|
WENDLING, PATRICE
|
|
2010
|
7 |
8 |
p. 379-380
2 p.
|
artikel
|
| 14 |
Ipilimumab emerges as first treatment to improve melanoma survival
|
MACNEIL, JANE SALODOF
|
|
2010
|
7 |
8 |
p. 379-
1 p.
|
artikel
|
| 15 |
Managing oral drugs: getting up to ‘MUSTER’
|
Bosserman, Linda D.
|
|
2010
|
7 |
8 |
p. 341-
1 p.
|
artikel
|
| 16 |
Nearly half of patients survive 2 years with bevacizumab, temozolomide, and radiotherapy-based glioblastoma regimen
|
HYER, RICHARD
|
|
2010
|
7 |
8 |
p. 373-374
2 p.
|
artikel
|
| 17 |
Oncologist shortage: is it an organizational problem?
|
Young, Patrick
|
|
2010
|
7 |
8 |
p. 384-
1 p.
|
artikel
|
| 18 |
Pancreatic cancer survival reaches new milestone with Folfirinox chemotherapy
|
WENDLING, PATRICE
|
|
2010
|
7 |
8 |
p. 381-382
2 p.
|
artikel
|
| 19 |
Radiation therapy helps cut locally advanced prostate cancer deaths by 43%
|
HYER, RICHARD
|
|
2010
|
7 |
8 |
p. 383-
1 p.
|
artikel
|
| 20 |
Sipuleucel-T immunotherapy for advanced prostate cancer
|
Abraham, Jame
|
|
2010
|
7 |
8 |
p. 342-344
3 p.
|
artikel
|
| 21 |
Skipping axillary dissection safe when sentinel node is negative
|
LONDON, SUSAN
|
|
2010
|
7 |
8 |
p. 370-371
2 p.
|
artikel
|
| 22 |
The conundrum of sipuleucel-T for prostate cancer
|
Knopf, Kevin B.
|
|
2010
|
7 |
8 |
p. 343-344
2 p.
|
artikel
|
Tijdschrift beschrijving